CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates new treatment strategies for hepatocellular carcinoma by targeting the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. It aims to develop selective mTORC1 inhibitors to enhance the efficacy of existing therapies.
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and the fourth leading cause of cancer-related deaths worldwide.
The multikinase inhibitor sorafenib is the only approved drug to treat HCC and on average enhances survival by three months.
Thus, the efficacy of current HCC treatment options is very limited.
Studies in the context of our ERC-Synergy grant revealed that sorafenib resistance correlates with upregulation of mammalian target of rapamycin complex 1 (mTORC1) signal…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
